Skip to main content

Table 2 Clinical trials evaluating the accuracy of sentinel lymph node dissection in clinically node-positive patients. Summary of trials designed to evaluate the accuracy of sentinel lymph node dissection to assess axillary nodal response to therapy in clinically node-positive patients who receive neoadjuvant chemotherapy

From: Targeting and limiting surgery for patients with node-positive breast cancer

Trial ACOSOG Z1071 [7, 33] SENTINA (Arm C) [9] SN FNAC [10]
Nodal eligibility criteria cN1-2 cN1-2 cN1-2
Endpoints reported for cN1 a
Biopsy required to confirm metastases? Yes No Yes
Number of patients cN1 = 603 592 153
cN2 = 34
Overall FNR (No IHC) 12.6 % a 14.2 % 13.4 %
FNR with IHC 8.7 % a Not reported 8.4 %
FNR depending on mapping agents    
One agent 20.3 % 16 % 16 %
Dual agents 10.8 % 8.6 % 5.2 %
FNR by number of SLNs    
One SLN 31 % 24.3 % 18.2 %
Two SLNs 21.1 % 18.5 % ≥2 SLNs = 4.9 %
Three or more SLNs 9.1 % 4.9 %
  1. aLimited to patients classified as cN1 with ≥2 sentinel lymph nodes removed
  2. FNR, False negative rate; IHC, Immunohistochemistry; SLN, Sentinel lymph node